Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen

Upton RA . Pharmacokinetic interactions between theophylline and other medications (Part I). Clin Pharmacokinet 1991;20: 66–80.

Asmus MJ Weinberger MM Milavetz G Marshik P Teresi ME Hendeles L . Apparent decrease in population clearance of theophylline: Implications for dosage. Clin Pharmacol Ther 1997;62: 483–9.

Eaton DL Gallagher EP Bammler TK Kunze KL . Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics 1995;5: 259–74.

Kerb R Brockmöller J Staffeldt B Ploch M Roots I . Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996;40: 2087–93.

Vandenbogaerde AL Geboes KR Cuveele JF Agostinis PM Merlevede WJ De Witte PA . Antitumour activity of photosensitized hypericin on A431 cell xenografts. Anticancer Res 1996;16: 1619–26.

Stansell JD Huang L . Pneumocystis carinii pneumonia. The medical management of AIDS. Philadelphia: WB Saunders Co., 1997: 275–300.

Rosse W Bunn HF . Hemolytic anemias. In: Isselbacher KJ Braunwald E Wilson JD Martin JB Fauci AS Kasper DL , eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill Inc., 1994: 1743–54.

Spivak JL Bender BS Quinn TC . Hematologic abnormalities in the acquired immunodeficiency syndrome. Am J Med 1984;77: 224–8.

Chalasani P Baffoe-Bonnie H Jurado RL . Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. South Med J 1994;87: 1145–6.

Prazuck T Semaille C Roques S . Fatal acute hemolysis in an AIDS patient treated with indinavir. AIDS 1998;12: 531–3.

Castaigne S Chomienne C Daniel MT Ballerini P Berger R Fenaux P All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76: 1704–9.

Chomienne C Ballerini P Balitrand N Daniel MT Fenaux P Castaigne S All-trans-retinoic acid in acute promyelocytic leukemias. II. In vitro studies: Structure– function relation. Blood 1990;76: 1710–7.

Chomienne C Ballerini P Balitrand N Amar M Bernard JF Boivin P Retinoic acid therapy for promyelocytic leukemia. Lancet 1989;2:746–7.

Chen ZX Xue YQ Zhang R Tao RF Xia XM Li C A clinical and experimental study on all-trans-retinoic acid—treated acute promyelocytic leukemic patients. Blood 1991;78:1413–9.

Huang ME Ye YC Chen SR Chai JR Lu JX Zhoa L Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567–72.

Warrell RP Frankel SR Miller WH Scheinberg DA Itri LM Hittelman WN Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385–93.

Regazzi MB Iacona I Gervasutti C Lazzarino M Toma S . Clinical pharmacokinetics of tretinoin. Clin Pharmacokinet 1997;32: 382–402.

Wong K Lim HL Teo CP Tan YO Kueh YK . Treatment of acute promyelocytic leukemia in first relapse with all-trans-retinoic acid. Ann Acad Med Singapore 1995;24: 177–9.

Tallman MS Andersen JW Schiffer CA Appelbaum FR Feusner JH Ogden A All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337: 1021–8.

Fenaux P Castaigne S Dombret H Archimbaud E Duarte M Morel P All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 1992;80:2176–81.

Frankel SR Eardley A Heller G Berman E Miller WH Dmitrovsky E All-trans-retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 1994;120: 278–86.

Frankel SR Eardley A Lauwers G Weiss M Warrell RP . The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992;117: 292–6.

Degos L Dombret H Chomienne C Daniel MT Miclea JM Chastang C All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643–53.

Deferoxamine. Therapy of aluminum toxicity. DRUGDEX, Vol 96. Denver, CO: Micromedex Inc., 1998.

Porter JB Huehns ER . The toxic effects of desferrioxamine. Baillieres Clin Haematol 1989;2: 459–74.

Davies SC Marcus RE Hungerford JL Miller MH Arden GB Huehns ER . Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;2: 181–4.

Armstrong D Hiramitsu T Gutteride J . Studies in experimentally induced retinal degeneration. Effect of lipid peroxides on ERG activities in the albino rat. Exp Eye Res 1982;35: 157–71.

Davies MJ Doukor R Dunster CA Gee CA Jonas S Willson RL . Desferrioxamine (Desferal) and superoxide free radicals. Formation of an enzyme-damaging nitroxide. Biochem J 1987;246: 725–9.

Good PA Claxson A Morris CI Blake DR . A model of desferrioxamine-induced retinopathy using the albino rat. Ophthalmologica 1990;201: 32–6.

Van der Meer FJM Rosendaal FR Vandenbrouke JP Briet E . Bleeding complications in oral anticoagulant therapy: An analysis of risk factors. Arch Intern Med 1993;153: 1557–62.

Begaud B Evreux JC Jouglard J Lagier G . Unexpected or toxic drug reaction assessment (imputation). Actualisation of the method used in France. Therapie 1985;40: 111–8.

Bartle WR Blakely JA . Potentiation of warfarin anticoagulant by acetaminophen (letter). JAMA 1991;265:1260.

The British Medical Association and The Royal Pharmaceutical Society. Appendix I: Interactions; warfarin and other coumarins. Br Natl Formul 1998;36: 586–7.

Hylek EM Heiman H Skates SJ Sheehan MA Singer DE . Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279: 657–62.